Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when MYGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: MYGN MYRIAD GENETICS INC 8-K

Myriad Genetics replaces CCO Brian Donnelly with internal promotion Vishal Sikri as EVP, Commercial

Filed September 16, 2026 · Period ending September 15, 2026 · ~1 min read

3 key changes 2 high relevance 2 sections

Key Changes

  • high

    Chief Commercial Officer Brian Donnelly is leaving the role effective September 16, 2026, and will remain as a non-executive employee through September 21, 2026 to assist with transition.

  • high

    Vishal Sikri, previously Senior Vice President of Product, has been appointed Executive Vice President, Commercial, effective September 16, 2026.

  • medium

    The company reaffirmed its full-year 2026 financial guidance as announced during its second quarter 2026 earnings call on July 30, 2026.

    Exhibit 99.1 view on EDGAR →

Summary

Myriad Genetics announced a leadership change in its commercial organization. Chief Commercial Officer Brian Donnelly is departing the role effective September 16, 2026, and will remain as a non-executive employee through September 21, 2026 to assist with the transition. The company did not state a reason for his departure.

Vishal Sikri, previously Senior Vice President of Product, has been promoted to Executive Vice President, Commercial, effective the same day. This internal succession provides continuity in the commercial leadership role. The company also reaffirmed its full-year 2026 financial guidance, which was previously announced during its second quarter 2026 earnings call. No specific figures were provided in this filing.

Section-by-Section Diff

Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation

~100 words

Myriad Genetics replaces its Chief Commercial Officer with an internal promotion to EVP, Commercial.

1 Added
Added New EVP, Commercial appointment medium

Added in current filing · verify on EDGAR →

the Company’s Board of Directors (the “Board”) appointed Vishal Sikri, currently serving as the Company’s Senior Vice President, Product, as the Company’s Executive Vice President, Commercial, effective September 16, 2026.

Vishal Sikri, previously SVP of Product, has been promoted to Executive Vice President, Commercial, taking over the commercial leadership role. The appointment is effective the same day as the outgoing CCO's departure. This is an internal succession.

Event · Exhibit 99.1

Myriad Genetics promotes Vishal Sikri to EVP-Commercial and announces CCO Brian Donnelly's departure, reaffirming FY2026 guidance.

1 Added
Added Executive departure medium

Added in current filing · view on EDGAR →

Brian Donnelly, who has served as Chief Commercial Officer since May of 2025, will be departing Myriad on September 21, 2026.

Chief Commercial Officer Brian Donnelly will leave the company on September 21, 2026. The press release thanks him for his contributions but does not state a reason for his departure.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 17, 2026 · How we verify